

趙 Chao Family Comprehensive Cancer Center



HYUNDAI Cancer Institute

CHOC Children's.

The Society for Adolescent and Young Adult Oncology (SAYAO), in conjunction with The University of California, Irvine and CHOC Children's Hyundai Cancer Institute

Invitation-Only 2016 Leukemia Think-Tank

From Pediatric to Adult Acute Lymphoblastic Leukemia: Integrating Immunotherapy, Enabled by Genomics, into Current Therapeutic Strategies

AGENDA

Newport Beach, California

Organizer/ Moderator:

Leonard Sender, MD CHOC Children's Hyundai Cancer Institute Executive Director Pediatric, Adolescent and Young Adult Cancer

Moonshot 2020 Project, Chan Soon-Shiong Institute of Molecular Medicine

Faculty Leaders:

Mark Litzow, MD Chair, Leukemia Committee, Eastern Cooperative Oncology Group (ECOG),

Mayo Clinic

Sima Jeha, MD Director, Leukemia/Lymphoma Developmental Therapeutics St Jude Children's Research Hospital

Monday November 14th 2016 – Tuesday November 15th 2016

| Monday | 12:00-19:00 |
|---------|-------------|
| Tuesday | 08:00-15:30 |

| Monday, 14 November 2016 | | |
|--------------------------|---|--|
| 12:00-12:30 | Registration and Refreshments – BALLROOM FOYER | |
| 12:30-12:45 | Introduction and Welcome Leonard Sender, MD | |
| l. | Immuno-Oncology | |
| 12:45-13:25 | Bio-Pharmaceutical: Clinical Updates Blinotumumab Gary Schiller, MD · UCLA Inotuzumab Ozogamycin Susan O'Brien, MD · UC Irvine | |
| 13:25-13:40 | Q & A Panel Session Moderator: Susan O'Brien, MD · UC Irvine CFCCC | |
| 13:40-15:00 | CAR-T Cell Clinical Updates: CAR-T Cells – Novartis/UPENN/CHOP Shannon Maude, MD • UPENN/ CHOP Kite Pharmaceutical Rajul Jain, MD, • Kite Pharma NCI Pediatric Branch Terry Fry, MD • NCI Pediatric Branch CAR-T cells and MSKCC Jae Park, MD • Memorial Sloan Kettering Cancer Center | |
| 15:00-15:30 | Q & A Panel Session Moderator: Lennie Sender, MD | |
| 15:30-16:00 | BREAK | |
| | | |
| II. | Asparginase Intensive vs Non Asparginase Regimens | |
| II. 16:00-17:20 | Asparginase Intensive vs Non Asparginase Regimens Moving forward in pediatric ALL: • What is the COG doing? Michael Burke, MD · Children's Hospital of Wisconsin Moving forward in AYA ALL: • C10403 Wendy Stock, MD · University of Chicago Moving forward in adult ALL: • MSKCC- Asparaginase-Intensive Adult ALL Dan Douer, MD · USC • MD Anderson - Hyper-CVAD and Beyond Elias Jabbour, MD · MD Anderson | |
| | Moving forward in pediatric ALL: What is the COG doing? Michael Burke, MD · Children's Hospital of Wisconsin Moving forward in AYA ALL: C10403 Wendy Stock, MD · University of Chicago Moving forward in adult ALL: MSKCC- Asparaginase-Intensive Adult ALL Dan Douer, MD · USC MD Anderson - Hyper-CVAD and Beyond | |
| 16:00-17:20 | Moving forward in pediatric ALL: What is the COG doing? Michael Burke, MD · Children's Hospital of Wisconsin Moving forward in AYA ALL: C10403 Wendy Stock, MD · University of Chicago Moving forward in adult ALL: MSKCC- Asparaginase-Intensive Adult ALL Dan Douer, MD · USC MD Anderson - Hyper-CVAD and Beyond Elias Jabbour, MD · MD Anderson | |

| | Tuesday, 15 November, 2016 |
|--|---|
| 7:00-8:00 | BREAKFAST – CABANA ROOM |
| III. | Plenary |
| 8:00-9:00 | Cancer Moonshot 2020 and Quantum Immuno-Oncology Lifelong Trials (QUILT) Patrick Soon-Shiong, MD · NantWorks |
| IV. | Clinical Research Trials |
| 9:00-9:30 | St Jude's New Leukemia Protocols –holistic approach to basic science, clinical care and survivorship Sima Jeha, MD · St. Jude Children's Research Hospital Hiroto Inaba, MD PhD · St. Jude Children's Research Hospital |
| 9:30-9:50 | Q & A Panel Session Moderator: Wendy Stock, MD · University of Chicago |
| 9:50-10:00 | BREAK |
| V. | Minimal/Measurable Residual Disease |
| 10:00-10:30 | What really goes wrong during leukemia transformation: Dysregulation of gene product expression Mike Loken, PhD · Hematologics, Inc/Affiliate Investigator the Fred Hutchinson Cancer Research Center |
| 10:30-10:50 | Q & A Panel Session Moderator: Sima Jeha, MD · St. Jude Children's Research Hospital |
| 10:50-11:10 | BREAK |
| - | |
| VI. | Leukemia – What's next |
| | Leukemia – What's next ECOG Leukemia Group Mark Litzow, MD · Mayo Clinic Imperatives and Controversies |
| VI. | Leukemia – What's next ECOG Leukemia Group Mark Litzow, MD · Mayo Clinic |
| VI. 11:10-11:50 | Leukemia – What's next ECOG Leukemia Group Mark Litzow, MD · Mayo Clinic Imperatives and Controversies Paul Gaynon, MD · USC |
| VI. 11:10-11:50 11:50-12:10 | Leukemia – What's next ECOG Leukemia Group Mark Litzow, MD · Mayo Clinic Imperatives and Controversies Paul Gaynon, MD · USC Q & A Panel Discussion Moderator: Lennie Sender, MD Kids vs Cancer and Compassionate Use Drugs |
| VI. 11:10-11:50 <u>11:50-12:10</u> 12:10-12:20 | Leukemia – What's next ECOG Leukemia Group Mark Litzow, MD · Mayo Clinic Imperatives and Controversies Paul Gaynon, MD · USC Q & A Panel Discussion Moderator: Lennie Sender, MD Kids vs Cancer and Compassionate Use Drugs Beth Anne Baber, PhD · The Nicholas Conor Institute for Pediatric Cancer Research |
| VI. 11:10-11:50 11:50-12:10 12:10-12:20 12:20-13:20 | Leukemia – What's next ECOG Leukemia Group Mark Litzow, MD · Mayo Clinic Imperatives and Controversies Paul Gaynon, MD · USC Q & A Panel Discussion Moderator: Lennie Sender, MD Kids vs Cancer and Compassionate Use Drugs Beth Anne Baber, PhD · The Nicholas Conor Institute for Pediatric Cancer Research LUNCH – ADJACENT TO BALLROOM FOYER |
| VI. 11:10-11:50 11:50-12:10 12:10-12:20 12:20-13:20 VII. | Leukemia – What's next ECOG Leukemia Group Mark Litzow, MD · Mayo Clinic Imperatives and Controversies Paul Gaynon, MD · USC Q & A Panel Discussion Moderator: Lennie Sender, MD Kids vs Cancer and Compassionate Use Drugs Beth Anne Baber, PhD · The Nicholas Conor Institute for Pediatric Cancer Research LUNCH – ADJACENT TO BALLROOM FOYER Stem Cell Transplantation What is the ROLE of stem cell transplantation in the new world of immune- biopharmaceuticals and CAR-T cells Michael Burke, MD · Children's Hospital of Wisconsin What is NEW in the field of stem cell transplantation that could influence leukemia care in the new world of immune- biopharmaceuticals and NK cells |
| VI. 11:10-11:50 11:50-12:10 12:10-12:20 12:20-13:20 VII. 13:20-14:20 | Leukemia – What's next ECOG Leukemia Group Mark Litzow, MD · Mayo Clinic Imperatives and Controversies Paul Gaynon, MD · USC Q & A Panel Discussion Moderator: Lennie Sender, MD Kids vs Cancer and Compassionate Use Drugs Beth Anne Baber, PhD · The Nicholas Conor Institute for Pediatric Cancer Research LUNCH – ADJACENT TO BALLROOM FOYER Stem Cell Transplantation What is the ROLE of stem cell transplantation in the new world of immune- biopharmaceuticals and CAR-T cells Michael Burke, MD · Children's Hospital of Wisconsin What is NEW in the field of stem cell transplantation that could influence leukemia care in the new world of immune- biopharmaceuticals and NK cells Jeffrey Miller, MD · University of Minnesota |